Download PDF
Homœopathic Links 2016; 29(02): 091-096
DOI: 10.1055/s-0036-1582473
Vaccinations
Thieme Medical and Scientific Publishers Private Ltd.

First Do No Harm: Scientific Evidence Implicating Allopathic Vaccination

Neil Z. Miller
1   United States
› Author Affiliations
Further Information

Publication History

Publication Date:
14 June 2016 (online)

    Permissions and Reprints

Abstract

Allopathic vaccination has many scientifically documented safety deficits that counteract well-publicised benefits. Thimerosal and aluminium, common ingredients in vaccines, can cause neurologic, immunologic and developmental harm. The pertussis vaccine has induced pertussis microorganisms associated with whooping cough to mutate and become more virulent. People vaccinated against pertussis can be asymptomatic carriers and transmitters of the disease, rendering herd immunity, or community immunity, unlikely. People vaccinated against measles can spread the disease to other fully vaccinated people. The MMR (measles-mumps-rubella) vaccine increases the probability of requiring emergency care. It also increases the risk of seizures and thrombocytopenia, a serious bleeding disorder. Infections experienced during childhood, such as measles, mumps and chickenpox, encourage normal development of the immune system in most children, offering protection against heart disease, strokes and cancer in adulthood. Vaccines—which are designed to prevent infections—increase cancer rates.

Keywords

vaccination - immunisation - thimerosal - pertussis - measles - MMR vaccine
 

  • References

  • 1 Gallagher CM, Goodman MS. Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997–2002. J Toxicol Environ Health A 2010; 73 (24) 1665-1677
    CrossrefPubMedGoogle Scholar
  • 2 Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003; 228 (6) 660-664
    PubMedGoogle Scholar
  • 3 Verstraeten T, Davis R, Gu D , et al. Increased risk of developmental neurologic impairment after high exposure to thimerosal-containing vaccine in first month of life. Proceedings of the Epidemic Intelligence Service Annual Conference, vol. 49. Atlanta, GA: Centers for Disease Control and Prevention; April 2000. http://mercury-freedrugs.org/docs . Accessed 29 March 2016
    PubMedGoogle Scholar
  • 4 Mrozek-Budzyn D, Majewska R, Kieltyka A, Augustyniak M. Neonatal exposure to Thimerosal from vaccines and child development in the first 3 years of life. Neurotoxicol Teratol 2012; 34 (6) 592-597
    CrossrefPubMedGoogle Scholar
  • 5 Miller NZ. Miller's Review of Critical Vaccine Studies: 400 Important Scientific Papers Summarized for Parents and Researchers. Santa Fe, New Mexico: New Atlantean Press; 2016: 20 , 34, 35, 62, 90, 102, 228–247
    Google Scholar
  • 6 Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus 2012; 21 (2) 184-189
    CrossrefPubMedGoogle Scholar
  • 7 Khan Z, Combadière C, Authier FJ , et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med 2013; 11: 99
    CrossrefPubMedGoogle Scholar
  • 8 Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 2012; 21 (2) 223-230
    CrossrefPubMedGoogle Scholar
  • 9 Mooi FR, van Loo IH, van Gent M , et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009; 15 (8) 1206-1213
    CrossrefPubMedGoogle Scholar
  • 10 Lavine J, Broutin H, Harvill ET, Bjørnstad ON. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine 2010; 29 (1) 11-16
    CrossrefPubMedGoogle Scholar
  • 11 Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 2014; 111 (2) 787-792
    CrossrefPubMedGoogle Scholar
  • 12 De Serres G, Markowski F, Toth E , et al. Largest measles epidemic in North America in a decade—Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis 2013; 207 (6) 990-998
    CrossrefPubMedGoogle Scholar
  • 13 Rosen JB, Rota JS, Hickman CJ , et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58 (9) 1205-1210
    CrossrefPubMedGoogle Scholar
  • 14 Wilson K, Hawken S, Kwong JC , et al. Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis. PLoS ONE 2011; 6 (12) e27897
    CrossrefPubMedGoogle Scholar
  • 15 Vestergaard M, Hviid A, Madsen KM , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292 (3) 351-357
    CrossrefPubMedGoogle Scholar
  • 16 Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 2007; 165 (6) 704-709
    CrossrefPubMedGoogle Scholar
  • 17 Rinaldi M, Perricone C, Ortega-Hernandez OD, Perricone R, Shoenfeld Y. Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. Lupus 2014; 23 (6) 554-567
    CrossrefPubMedGoogle Scholar
  • 18 Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum Vaccin 2007; 3 (2) 59-63
    CrossrefPubMedGoogle Scholar
  • 19 Kubota Y, Iso H, Tamakoshi A ; JACC Study Group. Association of measles and mumps with cardiovascular disease: The Japan Collaborative Cohort (JACC) study. Atherosclerosis 2015; 241 (2) 682-686
    CrossrefPubMedGoogle Scholar
  • 20 Pesonen E, Andsberg E, Ohlin H , et al. Dual role of infections as risk factors for coronary heart disease. Atherosclerosis 2007; 192 (2) 370-375
    CrossrefPubMedGoogle Scholar